GLP1R agonists like lixisenatide, exenatide, or semaglutide limit the progression of motor dysfunction in Parkinson’s disease.
GLP1R agonists like lixisenatide, exenatide, or semaglutide limit the progression of motor dysfunction in Parkinson’s disease.